Solifenacin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Urinary Bladder, Overactive
Conditions
Urinary Bladder, Overactive, Overactive Bladder
Trial Timeline
Apr 1, 2009 → Jun 1, 2010
NCT ID
NCT00979472About Solifenacin
Solifenacin is a approved stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT00979472. Target conditions include Urinary Bladder, Overactive, Overactive Bladder.
What happened to similar drugs?
20 of 20 similar drugs in Urinary Bladder, Overactive were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02087098 | Pre-clinical | Completed |
| NCT01642277 | Phase 2 | Completed |
| NCT01559389 | Approved | Completed |
| NCT01314781 | Approved | Completed |
| NCT01799902 | Pre-clinical | Completed |
| NCT01505439 | Approved | Completed |
| NCT01318837 | Approved | Completed |
| NCT02667470 | Approved | Completed |
| NCT01122563 | Pre-clinical | Completed |
| NCT00985387 | Pre-clinical | Completed |
| NCT00979472 | Approved | Completed |
| NCT00884104 | Approved | Completed |
| NCT00852696 | Pre-clinical | Terminated |
Competing Products
20 competing products in Urinary Bladder, Overactive